JP2022500410A5 - - Google Patents
Info
- Publication number
- JP2022500410A5 JP2022500410A5 JP2021513868A JP2021513868A JP2022500410A5 JP 2022500410 A5 JP2022500410 A5 JP 2022500410A5 JP 2021513868 A JP2021513868 A JP 2021513868A JP 2021513868 A JP2021513868 A JP 2021513868A JP 2022500410 A5 JP2022500410 A5 JP 2022500410A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antagonist
- heavy chain
- light chain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730772P | 2018-09-13 | 2018-09-13 | |
| US62/730,772 | 2018-09-13 | ||
| US201862755844P | 2018-11-05 | 2018-11-05 | |
| US62/755,844 | 2018-11-05 | ||
| PCT/US2019/050122 WO2020055702A1 (en) | 2018-09-13 | 2019-09-09 | Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500410A JP2022500410A (ja) | 2022-01-04 |
| JP2022500410A5 true JP2022500410A5 (https=) | 2022-09-01 |
| JP7470105B2 JP7470105B2 (ja) | 2024-04-17 |
Family
ID=69776882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513868A Active JP7470105B2 (ja) | 2018-09-13 | 2019-09-09 | 非マイクロサテライト高不安定性／ミスマッチ修復の良好な結腸直腸がんを処置するためのｐｄ－１アンタゴニストおよびｌａｇ３アンタゴニストの組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210317214A1 (https=) |
| EP (1) | EP3849606A4 (https=) |
| JP (1) | JP7470105B2 (https=) |
| AU (1) | AU2019337547A1 (https=) |
| CA (1) | CA3111066A1 (https=) |
| WO (1) | WO2020055702A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| EP3880709A4 (en) * | 2018-11-05 | 2022-07-27 | Merck Sharp & Dohme Corp. | DOSING REGIME OF ANTI-LAG3 ANTIBODIES AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF CANCER |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| IL308476A (en) | 2021-05-14 | 2024-01-01 | Syndax Pharmaceuticals Inc | Inhibitors of the menin-mil interaction |
| WO2023164638A1 (en) * | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
| US20250295661A1 (en) * | 2022-05-09 | 2025-09-25 | Syndax Pharmaceuticals, Inc. | Menin-mll inhibitors for the treatment of cancer |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| JP6595458B2 (ja) * | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| CA2955612C (en) * | 2014-07-18 | 2022-05-17 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| US20170097333A1 (en) * | 2015-09-28 | 2017-04-06 | Merck Sharp & Dohme Corp. | Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents |
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| US10613092B2 (en) * | 2016-04-01 | 2020-04-07 | Agilent Technologies, Inc. | Scoring methods for anti-PD therapy eligibility and compositions for performing same |
| JP2019517512A (ja) * | 2016-06-03 | 2019-06-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 |
| WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
-
2019
- 2019-09-09 AU AU2019337547A patent/AU2019337547A1/en active Pending
- 2019-09-09 WO PCT/US2019/050122 patent/WO2020055702A1/en not_active Ceased
- 2019-09-09 US US17/274,531 patent/US20210317214A1/en not_active Abandoned
- 2019-09-09 JP JP2021513868A patent/JP7470105B2/ja active Active
- 2019-09-09 CA CA3111066A patent/CA3111066A1/en active Pending
- 2019-09-09 EP EP19859611.6A patent/EP3849606A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500410A5 (https=) | ||
| JP2017524715A5 (https=) | ||
| JP2024037894A5 (https=) | ||
| JP2019519499A5 (https=) | ||
| JP2018508483A5 (https=) | ||
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| MX2021011500A (es) | Anticuerpos multiespecificos egfr x cd28. | |
| IL318482A (en) | Pd-1 inhibitor for use in a method of treating skin cancer | |
| RU2014147867A (ru) | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов | |
| JP2018070648A5 (https=) | ||
| JP2019515008A5 (https=) | ||
| HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2017535257A5 (https=) | ||
| JP2020508317A5 (https=) | ||
| JP2022512750A5 (https=) | ||
| JP2016537383A5 (https=) | ||
| JP2018518454A5 (https=) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| JP2018522887A5 (https=) | ||
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| WO2015200806A3 (en) | Humanized anti-tau antibodies | |
| RU2011116112A (ru) | Биспецифические анти-egfr/анти-igf-1r антитела | |
| PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| JP2019524701A5 (https=) |